17 results
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
drugs to be covered under Medicare Part D; and
created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct … countries;
oversee the manufacturing of material for clinical trials or potential commercial sales;
develop a portfolio of compounds;
establish
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
drugs to be covered under Medicare Part D; and
created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct … countries;
oversee the manufacturing of material for clinical trials or potential commercial sales;
develop a portfolio of compounds;
establish
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
to be covered under Medicare Part D; and
created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct … countries;
oversee the manufacturing of material for clinical trials or potential commercial sales;
develop a portfolio of compounds;
establish a business
424B4
CHRO
Chromocell Therapeutics Corp.
20 Feb 24
Prospectus supplement with pricing info
5:30pm
, a marketing authorization application, and approvals in certain other countries;
oversee the manufacturing of material for clinical trials … ; and
created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research
424B4
CHRO
Chromocell Therapeutics Corp.
20 Feb 24
Prospectus supplement with pricing info
5:28pm
. New Drug Application (“NDA”) for filing with the FDA, a marketing authorization application, and approvals in certain other countries;
oversee … Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding
DRS/A
0moxxg xm
17 Oct 22
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next